Dynavax Technologies Stock Performance
| DVAX Stock | USD 11.80 0.46 4.06% |
The firm shows a Beta (market volatility) of 0.65, which means possible diversification benefits within a given portfolio. As returns on the market increase, Dynavax Technologies' returns are expected to increase less than the market. However, during the bear market, the loss of holding Dynavax Technologies is expected to be smaller as well. Dynavax Technologies has an expected return of -0.34%. Please make sure to confirm Dynavax Technologies information ratio, potential upside, as well as the relationship between the Potential Upside and rate of daily change , to decide if Dynavax Technologies performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Dynavax Technologies has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in May 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (0.79) | Five Day Return (5.58) | Year To Date Return (21.14) | Ten Year Return (26.36) | All Time Return (87.94) |
Last Split Factor 1:10 | Last Split Date 2014-11-10 |
1 | Investment Analysis - Stock Traders Daily | 01/29/2024 |
2 | Exercise or conversion by Ryan Spencer of 29750 shares of Dynavax Technologies subject to Rule 16b-3 | 02/06/2024 |
3 | Exercise or conversion by Ryan Spencer of 20833 shares of Dynavax Technologies subject to Rule 16b-3 | 02/13/2024 |
4 | Acquisition by Justin Burgess of 13500 shares of Dynavax Technologies at 12.48 subject to Rule 16b-3 | 02/15/2024 |
5 | Disposition of 6667 shares by Justin Burgess of Dynavax Technologies subject to Rule 16b-3 | 02/16/2024 |
6 | Acquisition by Ryan Spencer of 402 shares of Dynavax Technologies subject to Rule 16b-3 | 02/20/2024 |
7 | Dynavax Technologies Corporation Q4 2023 Earnings Call Transcript | 02/23/2024 |
8 | Dynavax Secures New Sublease Agreement Amidst Zymergens Bankruptcy - TipRanks.com - TipRanks | 03/12/2024 |
9 | How vaccine maker Dynavax tested itself and found a corporate cure | 03/15/2024 |
10 | Wall Street Analysts See a 70.61 percent Upside in Dynavax Technologies Can the Stock Really Move This High - Yahoo Lifestyle Australia | 03/18/2024 |
11 | Technical Pivots with Risk Controls - Stock Traders Daily | 03/21/2024 |
12 | Those who invested in Dynavax Technologies five years ago are up 68 | 03/25/2024 |
13 | Disposition of 70000 shares by John Slebir of Dynavax Technologies at 12.48 subject to Rule 16b-3 | 03/28/2024 |
14 | Dynavax Technologies Co. Sees Large Increase in Short Interest - MarketBeat | 04/02/2024 |
15 | Disposition of 88000 shares by John Slebir of Dynavax Technologies at 11.12 subject to Rule 16b-3 | 04/05/2024 |
16 | Global Vaccine Adjuvants Market Size To Worth USD 1.51 Billion By 2033 CAGR of 3.9 | 04/17/2024 |
| Begin Period Cash Flow | 202.2 M |
Dynavax |
Dynavax Technologies Relative Risk vs. Return Landscape
If you would invest 1,418 in Dynavax Technologies on January 20, 2024 and sell it today you would lose (284.00) from holding Dynavax Technologies or give up 20.03% of portfolio value over 90 days. Dynavax Technologies is currently does not generate positive expected returns and assumes 1.5017% risk (volatility on return distribution) over the 90 days horizon. In different words, 13% of stocks are less volatile than Dynavax, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Dynavax Technologies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Dynavax Technologies' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Dynavax Technologies, and traders can use it to determine the average amount a Dynavax Technologies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2284
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | DVAX |
Estimated Market Risk
| 1.5 actual daily | 13 87% of assets are more volatile |
Expected Return
| -0.34 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.23 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Dynavax Technologies is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Dynavax Technologies by adding Dynavax Technologies to a well-diversified portfolio.
Dynavax Technologies Fundamentals Growth
Dynavax Stock prices reflect investors' perceptions of the future prospects and financial health of Dynavax Technologies, and Dynavax Technologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Dynavax Stock performance.
| Return On Equity | -0.0106 | ||||
| Return On Asset | -0.0192 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | (0.12) % | ||||
| Current Valuation | 995.78 M | ||||
| Shares Outstanding | 130.86 M | ||||
| Price To Earning | 6.95 X | ||||
| Price To Book | 2.49 X | ||||
| Price To Sales | 6.67 X | ||||
| Revenue | 232.28 M | ||||
| Gross Profit | 448.22 M | ||||
| EBITDA | 20.98 M | ||||
| Net Income | (6.39 M) | ||||
| Cash And Equivalents | 518.17 M | ||||
| Cash Per Share | 4.10 X | ||||
| Total Debt | 256.91 M | ||||
| Debt To Equity | 0.61 % | ||||
| Current Ratio | 2.77 X | ||||
| Book Value Per Share | 4.80 X | ||||
| Cash Flow From Operations | 100.56 M | ||||
| Earnings Per Share | (0.05) X | ||||
| Market Capitalization | 1.48 B | ||||
| Total Asset | 997.1 M | ||||
| Retained Earnings | (930.58 M) | ||||
| Working Capital | 796.92 M | ||||
| Current Asset | 199.95 M | ||||
| Current Liabilities | 28.79 M | ||||
About Dynavax Technologies Performance
To evaluate Dynavax Technologies Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Dynavax Technologies generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Dynavax Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Dynavax Technologies market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Dynavax's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 387.72 | 726.55 | |
| Return On Tangible Assets | (0.01) | (0.01) | |
| Return On Capital Employed | (0.04) | (0.04) | |
| Return On Assets | (0.01) | (0.01) | |
| Return On Equity | (0.01) | (0.01) |
Things to note about Dynavax Technologies performance evaluation
Checking the ongoing alerts about Dynavax Technologies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Dynavax Technologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Dynavax Technologies generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 232.28 M. Net Loss for the year was (6.39 M) with profit before overhead, payroll, taxes, and interest of 448.22 M. | |
| Dynavax Technologies has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Global Vaccine Adjuvants Market Size To Worth USD 1.51 Billion By 2033 CAGR of 3.9 |
- Analyzing Dynavax Technologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Dynavax Technologies' stock is overvalued or undervalued compared to its peers.
- Examining Dynavax Technologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Dynavax Technologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Dynavax Technologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Dynavax Technologies' stock. These opinions can provide insight into Dynavax Technologies' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dynavax Technologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Dynavax Stock please use our How to Invest in Dynavax Technologies guide.Note that the Dynavax Technologies information on this page should be used as a complementary analysis to other Dynavax Technologies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for Dynavax Stock analysis
When running Dynavax Technologies' price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Stocks Directory Find actively traded stocks across global markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |
Is Dynavax Technologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dynavax Technologies. If investors know Dynavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dynavax Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (0.05) | Revenue Per Share 1.804 | Quarterly Revenue Growth (0.70) | Return On Assets (0.02) |
The market value of Dynavax Technologies is measured differently than its book value, which is the value of Dynavax that is recorded on the company's balance sheet. Investors also form their own opinion of Dynavax Technologies' value that differs from its market value or its book value, called intrinsic value, which is Dynavax Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dynavax Technologies' market value can be influenced by many factors that don't directly affect Dynavax Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dynavax Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dynavax Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dynavax Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.